Want to see IN:HALEOSLABS full AI Analyst Report?
Top Page
SMS Lifesciences India Ltd.
(HALEOSLABS)
Select Model
Select Model
Rating:58Neutral
Price Target:
₹1,508.00
▲(36.47% Upside)
Action:Reiterated
Date:07/02/26
The score is held back primarily by pressured profitability and a deterioration to negative free cash flow, despite strong FY2026 revenue growth and a generally manageable balance sheet. Technically, the stock remains supported by trading above major moving averages, but momentum is mixed. Valuation is supported by a high dividend yield, though the P/E remains elevated.
Positive Factors
FY2026 Revenue Rebound
The sharp FY2026 revenue rebound indicates improving demand for the company’s API and intermediate products after a mixed prior growth pattern. Sustained sales recovery would improve manufacturing utilization, support fixed-cost absorption, and provide a stronger base for rebuilding profitability.
Negative Factors
Severe Gross Margin Compression
The steep gross-margin decline shows that stronger sales are converting less efficiently into gross profit, potentially reflecting unfavorable pricing, product mix, or input economics. If this compression persists, it will limit reinvestment capacity and make revenue growth less valuable to shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
FY2026 Revenue Rebound
The sharp FY2026 revenue rebound indicates improving demand for the company’s API and intermediate products after a mixed prior growth pattern. Sustained sales recovery would improve manufacturing utilization, support fixed-cost absorption, and provide a stronger base for rebuilding profitability.
Read all positive factors
SMS Lifesciences India Ltd. (HALEOSLABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹4.45B
Dividend Yield0.1%
Average Volume (3M)37.00
Price to Earnings (P/E)28.6
Beta (1Y)1.06
Revenue Growth-3.12%
EPS Growth-8.49%
CountryIN
Employees611
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)48.10
Shares Outstanding3,023,287
10 Day Avg. Volume19
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio-1.50
Price to Book (P/B)1.69
Price to Sales (P/S)1.08
P/FCF Ratio-15.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SMS Lifesciences India Ltd. Business Overview & Revenue Model
Company Description
Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applica...
How the Company Makes Money
SMS Lifesciences India Ltd. primarily makes money by manufacturing and selling APIs (bulk drugs) and related pharmaceutical intermediates to customers such as generic drug manufacturers and other pharma companies that formulate finished medicines....
SMS Lifesciences India Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
66
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.47B | 3.34B | 3.37B | 3.00B | 3.13B | 3.47B |
| Gross Profit | 893.12M | 480.08M | 1.17B | 907.68M | 845.45M | 875.42M |
| EBITDA | 363.12M | 446.77M | 496.44M | 347.37M | 338.06M | 484.37M |
| Net Income | 145.41M | 173.12M | 201.09M | 90.93M | 114.63M | 253.22M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 4.54B | 3.90B | 3.91B | 3.95B | 3.57B |
| Cash, Cash Equivalents and Short-Term Investments | 11.92M | 23.69M | 15.08M | 14.93M | 36.10M | 33.56M |
| Total Debt | 0.00 | 1.11B | 864.09M | 1.01B | 1.00B | 795.98M |
| Total Liabilities | -2.03B | 2.25B | 1.78B | 1.98B | 2.07B | 1.92B |
| Stockholders Equity | 2.03B | 2.14B | 1.97B | 1.77B | 1.69B | 1.52B |
Cash Flow | ||||||
| Free Cash Flow | 262.34M | -228.98M | 187.06M | 34.38M | -338.56M | -623.94M |
| Operating Cash Flow | 457.63M | 349.64M | 340.55M | 243.06M | 146.95M | -112.41M |
| Investing Cash Flow | -192.05M | -579.69M | -149.98M | -184.50M | -312.92M | -71.43M |
| Financing Cash Flow | -262.87M | 237.10M | -191.24M | -65.64M | 168.88M | 108.33M |
SMS Lifesciences India Ltd. Technical Analysis
Negative
1105.00
Price Trends
1522.40
Negative
1519.26
Negative
1411.49
Positive
Market Momentum
-8.19
Positive
46.13
Neutral
65.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HALEOSLABS, the sentiment is Negative. The current price of 1105 is below the 20-day moving average (MA) of 1497.49, below the 50-day MA of 1522.40, and below the 200-day MA of 1411.49, indicating a neutral trend. The MACD of -8.19 indicates Positive momentum. The RSI at 46.13 is Neutral, neither overbought nor oversold. The STOCH value of 65.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:HALEOSLABS.
SMS Lifesciences India Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹152.13B | 55.58 | ― | 0.52% | -6.72% | -22.67% | |
71 Outperform | ₹70.80B | 36.54 | ― | 0.11% | 28.14% | 11.38% | |
58 Neutral | ₹4.45B | 28.56 | ― | 0.10% | -3.12% | -8.49% | |
56 Neutral | ₹25.38B | 37.27 | ― | 0.11% | -20.86% | -34.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹153.45B | 69.13 | ― | 0.33% | -3.41% | -56.45% | |
49 Neutral | ₹609.00B | 111.76 | ― | 0.13% | 9.83% | 5.07% |
* General Sector Average
IN:HALEOSLABS
SMS Lifesciences India Ltd.
1,473.30
250.88
20.52%
IN:BIOCON
Biocon Limited
380.00
12.09
3.29%
IN:CONCORDBIO
Concord Biotech Ltd.
1,462.10
-183.84
-11.17%
IN:DCAL
Dishman Carbogen Amcis Ltd.
162.05
-123.95
-43.34%
IN:SUPRIYA
Supriya Lifescience Limited
898.75
211.82
30.84%
IN:SYNGENE
Syngene International Ltd.
379.95
-276.54
-42.12%
SMS Lifesciences India Ltd. Corporate Events
Haleos Labs Sets 20th AGM to Approve FY26 Results, Dividend and New Auditor
Sep 8, 2026
Haleos Labs Limited has convened its 20th Annual General Meeting for September 30, 2026, to be conducted via video conferencing and other audio-visual means, reflecting ongoing use of digital platforms for shareholder engagement. Shareholders will...
Haleos Labs Publishes Notices for 20th AGM in Line with SEBI Norms
Sep 8, 2026
Haleos Labs Limited, formerly SMS Lifesciences India Ltd., is a Hyderabad-based pharmaceutical and life sciences company listed on BSE and NSE under the symbol HALEOSLABS. It uses regional and national business newspapers to disseminate investor i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.